跳至主要内容
临床试验/NCT03089450
NCT03089450Unknown不适用

A Multicenter, Subject-blinded, Randomized Study to Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent in Patients Undergoing Drug-eluting Stent Procedure After Coronary Angiography

CGBio Inc.1 个研究点 分布在 1 个国家目标入组 112 人开始时间: 2017年3月22日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
112
试验地点
1
主要终点
in-segment late loss

研究概览

简要总结

to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)

详细描述

A Multicenter, subject-blinded, randomized study to evaluate safety and efficacy of CGBIO stent compared to Biomatrix Flex stent in patients undergoing drug-eluting stent procedure after coronary angiography

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least one lesion with a diameter stenosis >50%
  • suitable for coronary stent implantation in a vessel with a reference diameter ranging from 2.5 mm to 4.0 mm;
  • Gr 1 ≤TIMI flow

排除标准

  • ST-segment elevation MI
  • Bifurcation lesion
  • Chronic total occulusion
  • Restenosis lesion
  • Graft vessel lesion
  • Patient has a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated or in which patient will not be able to comply with dual antiplatelet therapy for at least 1 year
  • Cardiogenic shock or hemodynamic compromise
  • Existing impairment in liver and kidney.

结局指标

主要结局

in-segment late loss

时间窗: 9 month

angiographic in-segment late loss measure by QCA program

次要结局

  • in-stent late loss(9 month)
  • MACE(9 month)
  • Restenosis rate(9month)

研究者

发起方
CGBio Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验